Sugi Predict

Sugi Predict / Compounds / SCHEMBL640432

SCHEMBL640432

SCHEMBL640432

COC(=O)C(c1ccc(OC)cc1)n1c(=O)n(C(=O)OC(C)(C)C)c2ccc(Cl)cc21

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 3/20 0.41
▸ EGFR P00533 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ PTGS2 P35354 1/20 0.35
▸ CNR2 P34972 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ NR3C2 P08235 1/20 0.34
▸ CCR2 P41597 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ GPR139 Q6DWJ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640686 0.90 MEN1 (0.38) LMNAL3MBTL1MEN1KMT2APTGS2
SCHEMBL642618 0.84 LMNA (0.41) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL639820 0.83 LMNA (0.38) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL642977 0.82 LMNA (0.44) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL641167 0.80 L3MBTL1 (0.48) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL640641 0.76 LMNA (0.37) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL640324 0.76 MEN1 (0.41) LMNAL3MBTL1MEN1KMT2APTGS2
SCHEMBL639895 0.71 GABRG2 (0.41) MDM2
SCHEMBL639740 0.71 MDM2 (0.46) MDM2LMNAL3MBTL1MEN1KMT2A
SCHEMBL31324168 0.70 PSEN1 (0.52) PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 — — US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 — — US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 — — US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 — — US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 — — EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MDM2 1402/4885EGFR 4394/4885LMNA 886/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A MDM2 1402/4885EGFR 4394/4885LMNA 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.